Volkswagen Group Diesel Efficiency Foundation (VGDES) and the Consumentenbond Announce that Court Once Again Rules Against Volkswagen in Dutch Dieselgate Proceedings
On Friday October 6, 2023, the Sub-District Court of Oost-Brabant (‘s-Hertogenbosch) ruled that Volkswagen must compensate yet another Dutch Dieselgate consumer who purchased a VW vehicle containing illegal defeat device software. The Court ruled that Volkswagen must pay €4440 - the equivalent of 10% of the vehicle’s purchase price.
This is the latest of four lawsuits brought by the Volkswagen Group Diesel Efficiency Foundation (VGDES) (a Dutch organization representing consumer rights) and Consumentenbond (the Dutch consumer rights organization) on behalf of consumers defrauded by VW. Earlier this year, in March, April and July 2023, other Dutch courts all ruled against Volkswagen finding that it must pay damages to Dutch consumers who similarly purchased vehicles equipped with illegal software. In those prior rulings, the courts awarded €3,000 for an impacted new VW diesel vehicle and €1,500 for a used one. In this latest opinion, the judge increased the penalty finding that those amounts were too low, and determining that the appropriate sanction was a percentage of the vehicle’s purchase price.
A Fourth Defeat for Volkswagen
“This is the fourth time in a row that the Court has ruled against Volkswagen,” said Dick Bouma, chairman of VGDES. “The judge swept aside all VW’s technical legal defenses, and simply found that the car maker deceived consumers. Courts here and all over the world have determined that the company has deliberately misled consumers, including by promoting these diesel cars as environmentally friendly. It is time for Volkswagen to compensate harmed consumers.”
Volkswagen Should Resolve the Claims of the Hundreds of Thousands Dutch Consumers
Sandra Molenaar, Consumentenbond CEO, is pleased with the ruling and looks ahead: “So far we have won all four lawsuits against VW concerning its illegal use of defeat device software in diesel cars. Following this even stronger decision, we again invite Volkswagen to engage in settlement talks. Hopefully, the company is now prepared to compensate all affected Dutch consumers. If not, there are thousands of individual cases we can file against the Company. And, if necessary, we will take each and every case to court to hold Volkswagen accountable and to force the Company to compensate all impacted consumers.”
Links
- March: https://www.consumentenbond.nl/nieuws/2023/doorbraak-in-volkswagen-dieselschandaal-rechter-wijst-compensatie-toe
- April: https://www.consumentenbond.nl/nieuws/2023/weer-succes-in-rechtszaak-om-volkswagen-sjoemeldiesel
- July: https://www.consumentenbond.nl/nieuws/2023/volkswagen-moet-eigenaar-tweedehands-sjoemeldiesel-1500euro-betalen
- October: https://www.consumentenbond.nl/nieuws/2023/volkswagen-opnieuw-veroordeeld-in-dieselgate-procedure
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231011132017/en/
Contact information
Source/Contact
Gerard Spierenburg
Consumentenbond
gspierenburg@consumentenbond.nl
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom